Depression in HIV/AIDS patients affects adherence and disease progression and often goes unnoticed. DHIVA is a cross-sectional epidemiologic survey, investigating the prevalence of depression in people living with HIV through use of a validated self-administered scale , as well and the degree of concordance between the physician's perception and patients' reports. A total of 690 HIV-infected patients attending 24 centers across Italy were enrolled. Concordance was calculated by K statistics. Association between depression and subject characteristics were evaluated through univariate and multivariate logistic models (OR and 95% CI). The prevalence of depressive symptoms was 48.8% from patient's questionnaires and 49.5% from physicians' reports, with a low/fair concordance (K = .38, p < .001). CES-D-20 found severe depression in 22.5% of the patients vs 4% identified by physicians. 135/155 (87%) of the severely depressed patients (according to CES-D-20) were considered as non or mildly/moderately depressed by physicians. Risk of severe depression was associated with unemployment
Introduction
With the advent of highly active antiretroviral therapy (HAART), the disease pattern of HIV/AIDS has gradually evolved (Scandlyn, 2000) and the clinical approach to patients has changed, extending beyond pharmacological treatment and posing increasing attention towards the patient's overall well-being and quality of life. In particular, focus is being set on psychological distress and depression which are common to chronic conditions and which have been demonstrated to strongly influence clinical outcomes (Alciati et al., 2001; Hartzell, Janke, & Weintrob, 2008) .
Several studies have confirmed a high but variable prevalence of depression among HIV/AIDS patients ranging from 22% to 45% (Benton, 2008; Ciesla & Roberts, 2001; Penzak, Reddy, & Grimsley, 2000) . Despite these high-prevalence estimates there is evidence of an appreciable under-diagnosis of depressive symptoms, especially for severe depression (Asch et al., 2003; Rodkjaer et al., 2010; Rabkin, 2008) .
As in other chronic settings as in cancer or chronic heart diseases, recognizing depression in HIV/AIDS patients (especially severe depression) and discriminating it from other physiological and emotional states may be difficult for the lack of specific skills to diagnose mental disorders, lack of time in busy hospital settings, and reluctance of the patient to discuss emotional wellbeing (Krebber et al., 2014; Thombs et al., 2008) .
Consequently, appropriate depression individuation would generally require specific evaluation by a psychiatrist or psychologist (Gelenberg, 2009; Rabkin, 2008) . However, this type of support is not always available or included in the routine clinical protocols, being left to the single hospitals/centers' initiative which can introduce a significant risk of underestimation (Asch et al., 2003; Israelski et al., 2007) .
The aim of this study is to evaluate the extent of missed diagnoses of depression among HIV-infected subjects.
Patients and methods
The DHIVA study is a multicenter cross-sectional study involving 24 clinical HIV Centers across Italy. The primary objective of the study was to compare the degree of concordance between assessments of depression as evaluated by a validated screening tool, the Center of Epidemiologic Studies Depression scale (Radloff, 1977) and the perception of the attending physician. Secondary objectives were to assess the prevalence and the severity of depressive symptoms and to describe the correlates of depression.
The study was performed within a fixed 10-day timeframe, enrolling for each site a maximum of 30 consecutive outpatients among those regularly attending the center. Inclusion criteria were age >18, a diagnosis of HIV >6 months, and consent to inclusion in the study; the sole exclusion criterion was the patient's inability to fill out the questionnaire. The attending physicians were asked to evaluate their patients' depression status according to their clinical experience and classify it as absent, mild, moderate, or severe. Each patient enrolled was asked to fill out the self-assessment CES-D-20 questionnaire, that classified the subject into one of four categories: absence of depression, mild, moderate, and severe depression (CES-D-20 score categories: <16, 16-20; 21-25; 26-60, respectively) Patients were also given a second ad hoc questionnaire (the DHIVA questionnaire, Appendix - Figure A1 ) investigating subjective parameters and patients' behavioral and social indicators.
The study obtained approval/authorization by ethics committees as requested by local regulations. Prior to the inclusion in the study, all patients provided a signed informed consent form.
Statistical methods
All characteristics were described using frequency distributions for categorical variables and mean, median, standard deviation, interquartile range, and range for quantitative variables.
Agreement between physician's judgment and CES-D-20 results was assessed by means of Cohen's weighted kappa coefficient (Cohen, 1968) . The weight matrix allows the specification of the degree of the disagreement. K statistics were calculated using two differently weighted systems (W1 and W2), both based on the "proximity/closeness" of the judgments or the "seriousness" of the disagreement. In the first system, the decrease is constant (1-.66-.33-0), while the second assigns weights so as not to penalize trial contiguous classes (1-.89-.56-0) .
Data were analyzed through descriptive statistics and stratified according to the CES-D-20. Association between depression and subject characteristics were evaluated separately through univariate and multivariate logistic models (OR and 95% CI).
To perform univariate and multivariate logistic models, both diagnosis of depression (mild, moderate, and severe) and just severe depression were used as response variables and demographic/clinical conditions as regressors: multivariate logistic regression was performed with variables which were previously found with p < .20 in univariate logistic regression. From the regression model thus obtained the variables that had p-value >.10 were gradually excluded, one at a time. At each single step of the exclusion procedure the variable with the higher p-value was deleted, based on the value of the rank test.
Continuous variables were reported as mean +/− SD; comparisons were performed by a two-tailed independent samples t-test; discrete variables were reported as category counts; the comparisons were performed by a Pearson chi-square test.
Results
The study enrolled 709 patients: of these, 18 were excluded from the analysis due to inclusion criteria violation or incomplete questionnaires, resulting in 690 evaluable patients. The majority of patients were male (72.5%), Caucasian (96.5%), and between 45 and 54 years of age; a large proportion had primary/middle school education (47%), smoked (51%), and was not stably employed (38%) ( Table 1) . According to results attained by CES-D-20, 48.8% of respondents had some degree of depression: 14.3% of subjects had mild symptoms, 12.0% had moderate symptoms, and 22.5% had severe symptoms. According to the infectious disease physicians, 49.4% of patients suffered from depression: of these, 27% were classified as mild, 18.4% as moderate, and 4% as severe depression (Figure 1 ).
The degree of discrepancy/concordance between CES-D-20 results and clinical evaluation is reported in Table 2 . Concordance was full in 296 cases (42.9%), whereas in the remaining 57.1% the two judgments disagreed about the presence or degree of depression.
Specifically, in some cases clinicians considered as "not depressed" patients who were depressed according to , including 32 [4.6%] who were severely depressed). Conversely, some patients who were classified as not depressed by CES-D-20, were identified as depressed by physicians (n = 120; 17.4%).
Among patients classified as depressed by CES-D-20 (n = 337, Table 3), there was full concordance on the degree of depression in only 18.7% of cases (n = 63/ 337, dark grey boxes), while the depressive status was overestimated by physicians in 7.1% of cases (24/337) and underestimated in the remaining 74.2% (250/337; light grey boxes). Considering the CES-D-20 categories as a reference, physicians' underestimation was particularly high with regards to moderate (75.9%, n = 63/83) and severe depression (87.1%, n = 135/155).
The comparison of the concordance between the two assessments as measured by K statistics evidenced an overall fair (K = .31 according to W1) or moderate (K = .43 according to W2) concordance between the CES-D-20 and physicians' evaluation.
A high variability of concordance among participating centers (Figure 2 ) was also observed.
Factors associated with depression at the univariate level are reported in Appendix (Tables A1 and A2) .
Application of the multivariate model on clinical/ demographic data showed that the independent factors significantly associated with depression were: un-or under-employment, liver cirrhosis, previous diagnosis of depression, living in smaller households, unknown HBV status, and current use of illicit drugs (Table 4) . Multivariate analysis, with data derived from the DHIVA questionnaire, confirmed as independent correlates of depression the unsatisfactory perception of quality of life, sexual dysfunction (other than loss of libido), use of sleeping pills /sedatives, and non-adherence to antiretrovirals in the last week (Table 5 ).
The number of patients classified by CES-D-20 as having severe depression was 155 (22.46%). The variables found to be associated with severe grade of depression in the univariate model, are listed in the Appendix (Table A3 ) while the multivariate model is showed in Table 6 .
The parameters associated with concordance/discordance between the physician's judgment and the CES-D-20 assessment were analyzed at a univariate level. The previous diagnosis of depression and previous alcohol abuse are the factors that correlate with concordance between physicians' diagnosis of depression and CES-D-20 depression categories; the chance of being correctly recognized as depressed by the physician was 88% higher in patients with a previous diagnosis of depression (p < .001) and 76% higher in those using alcohol (p = .04). Conversely, depressed patients taking interferon for HCV co-infection had a 10-fold higher risk of not being recognized as depressed by the physician, compared to those not on interferon therapy (Appendix , Table A4 ).
Finally, the factors significantly involved in attributing depression by physicians to patients who were not depressed per CES-D-20 were: HBV or HCV co-infections (p = .0189 and p = .011), cirrhosis (p = .033), unknown education level (p = .018), employment status (p = .012), previous depression (p = .002), or treatment failure (p = .006) (Appendix, Table A5 ).
Discussion
In patients living with HIV/AIDS, depression has been reported to be associated with non-adherence to therapy (Horberg et al., 2008; Nel & Kagee, 2011) , faster progression of the disease (Kacanek et al., 2010; Pence et al., 2007) and diminished active and problem-focused coping strategy. Depression was considered as a main comorbidity (contributing, incidental, or confounder) for clinical assessment of HIV-associated neurocognitive disorder (HAND, Antinori et al., 2007) and a recent analysis of the CHARTER Research Cohort pointed out that major depressive disorder (MDD) is also linked to viral escape in CSF (Hammond, Crum, & Treisman, 2013) .
Despite the burden of depression in HIV/AIDS patients the diagnosis can be frequently missed in this population and it may be difficult to discriminate depressive symptoms from normal fluctuations in mood state. Although questionnaires cannot replace the doctor-patient relationship, self-administered depression scales are generally considered a valid screening tool. The CES-D-20 self-administered depression scale (Radloff, 1977) is widely used to screen for depression status among people with HIV and has proved to be a tool with high sensitivity and somewhat lower specificity (Balsamo & Saggino, 2007) . Prevalence of depression in our cohort was high (approximately half of the population, considering all grades of depression and for both the physician and CES-D-20 evaluation).
The two evaluations gave us different prevalence distribution when considering the different categories of depression, thus suggesting that even when a depressive status has been correctly identified it may be difficult to discriminate the depression severity.
Full concordance between CES-D-20 assessment and physicians' judgment on the presence and severity of depression was achieved only in less than one-fifth of cases.
Discrepancy between the physician's perception and the CES-D-20 assessment was found especially in relation to the degree of depression. Considering the CES-D-20 categories as a reference, overestimation occurred in a minority of cases, while underestimation was more common than expected. In particular, 87.1% of subjects with CES-D-20 scores placing them in the severely depressed category were not perceived to be severely depressed by their physicians, with potential consequences for the patients' health and clinical management. The underestimation of depression among patients taking interferon-alpha is especially noteworthy, as its neuropsychiatric side effects are widely described (Mello, Segurado, & Malbergier, 2010) .
It is conceivable that a certain degree of depression is considered by physicians so common in patients living with HIV/AIDS, as to be deemed the patient's baseline mood. Some HIV-related symptoms (e.g., fatigue) might further interfere with recognizing depression, and physicians might need specialized training to correctly diagnose depression in this setting.
It is important to note that the main concern of HIV physicians is to maintain an adequate suppression of HIV and an acceptable immunological function in patients, and this can lead them to overlook other clinically relevant aspects such as depression. Furthermore, attending physicians in Infectious Diseases units may not receive any specific training for depression diagnosis and care. We can speculate that the discrepancy of diagnostic accuracy across the participating centers could be explained also by the presence/absence of multidisciplinary teams that include mental health specialists, where it is possible that the multifaceted approach to global patients' health may lead them to monitor also nonstrictly virological aspects.
On the other hand, in the presence of HBV and/or HCV co-infection or cirrhotic liver disease, physicians tend to overestimate depression. In these cases, the peculiar Italian epidemiological picture of viral liver diseases (Sagnelli, et al., 2005; Sagnelli et al., 2008) and the high prevalence of drug abuse among HIV patients (Istituto Superiore di Sanità, 2013) may have a confounding effect on clinical judgment. Drug abuse has already been associated with an increased risk of psychological alterations (Psaros et al., 2013) and co-infections with hepatitis B and C viruses represented an additional risk factor for depression (Raison et al., 2006; Weiss & Morgello, 2009) . The association between unknown HBV status and depression found in our analysis does not have an obvious explanation: however, the number of patients with unknown HBV status was small (56 subjects), and this association is probably irrelevant. In our study hepatic cirrhosis was strongly associated with depressive symptoms, confirming previous reports (Mells et al., 2013) .
Lower educational level and unemployment status were among the most powerful factors associated with depression, with unemployment being a strong predictor for the highest degree of depressive status. Although depression can arise as consequence of patients not being involved in a working activity, depression itself might also be the cause for becoming less efficient in the workplace and eventually lead to losing the job or not maintaining it (Bravo et al., 2010; Raison et al., 2006) .
A very strong association has been detected between low perception of quality of life and depressive symptoms thus confirming existing data that suggest that psychological well-being and psychiatric comorbidities are important predictors of quality of life in this population (Briongos-figuero et al., 2011; Degroote et al., 2013; Douaihy & Singh, 2001 ). Nevertheless we have to take into account that many determinants of quality of life and of depression overlap, therefore the strength of the association may be due to confounders. As shown for other chronic disorders (Grenard et al., 2011) and also HIV infection (Gonzalez et al., 2011) , a strong association between depression and medication nonadherence has been found. Since it has been shown that antidepressant treatment improves antiretroviral adherence (Sin & DiMatteo, 2014) , clinicians should be aware of these two frequently coexisting conditions and always investigate patients diagnosed with depressive symptomatology for correct pill intake and vice versa. The number of previous treatment failures and female gender are specifically related to severe depression and did not emerge as correlate of risk for minor degrees of depression. In this respect, our data can be considered in agreement with the previously published literature (Ickovics et al., 2001) ; it is well established that women generally bear a greater combination of stress factors in relation to family planning, motherhood, lower income, and lack of emotional support compared to men (Mello et al., 2010; Rabkin, 2008) . Severe depression in women is also a predictor of disease progression and higher morbidity: depressed women with HIV/AIDS, however, are at increased risk for non-AIDS related deaths (Cook et al., 2004) .
In our study population living alone, sexual dysfunctions, use of sleeping pills were significantly associated with current depression, confirming that people living with HIV may require further clinical, social, and emotional support.
The main limitation of the study is that possible differences among clinicians about specific training and experience on neuropsychiatric aspects have not been collected. Additionally, it has to be taken into account that CES-D-20 is an epidemiological screening tool designed and validated to identify individuals at risk for clinical depression and not to provide a clinical diagnosis. Furthermore, we acknowledge that some symptoms (such as fatigue possibly associated with treatment or disease itself) may cause the CES-D to overestimate the depression thus it is possible that part of discrepancy might have been driven by CES-D-20 false positive or negative.
Finally, the cross-sectional design was suitable to demonstrate association between investigated factors and depressive symptoms, but not causality.
Conclusions
Our study confirms that depression is a very frequent condition among the HIV-positive population also in the HAART era. Factors associated with severe depressive symptomatology were principally socio-demographic characteristics, previous diagnosis of depression, and treatment failure. The most relevant finding of this study, however, was an alarming discrepancy between psychological evaluation obtained by means of a standardized screening tool and by the clinician's assessment. Although clinicians may benefit from more education and training on depression diagnosis, and recognizing the presence of depression correlates may lead to fewer missed diagnoses, the use of a self-reported scale, such as CES-D-20, could represent an immediate and costeffective screening tool for identifying patients with depressive symptomatology.
Nonetheless HIV has become a chronic infection that extends over several decades. Patients living with HIV/ AIDS may often have a low quality of life especially driven by psychological aspects rather than physical symptoms. Greater attention of clinician's towards the quality of life in persons living with HIV/AIDS is mandatory and needs a multidisciplinary approach.
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